A new approach to reducing the risk of ischemic stroke1

Watch FXIa inhibition in action

j

YYMMDD Author/Uploaded by

FXIa inhibition interrupts the feedback loop that amplifies thrombin generation1

Thrombin activates factor XI via a positive feedback loop in the intrinsic pathway, driving thrombus formation and stability.1
factor-xla

FXIa=activated factor XI.

Factor XIa inhibition targets more pathological clotting (thrombosis) with lesser impact on normal clotting response (hemostasis).1

References

  • SUNHARBO (asundexian) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; November 2026.
  • Fredenburgh JC, Weitz JI. Factor XI as a target for new anticoagulants. Hamostaseologie. 2021;41(2):104-110. doi:10.1055/a-1384-3715
  • Heitmeier S, Visser M, Tersteegen A, et al. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost. 2022;20(6):1400-1411. doi: 10.1111/jth.15700